Home-based screening for undiagnosed heart failure
Uppsala Self-SCREENing of Heart Failure Study
This study tests a new home screening method to see if it can help find undiagnosed heart failure in high-risk patients better than regular care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | Uppsala University Academic / other |
| Locations | 1 site (Uppsala) |
| Trial ID | NCT06940544 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates a stepwise multimodal home-based screening strategy using rapid point-of-care testing to detect undiagnosed heart failure in high-risk patients. It compares this approach to usual care to determine if it increases the diagnosis of heart failure within six months and leads to more patients receiving guideline-directed medical therapy. The study also evaluates the long-term impact of earlier diagnosis on hospitalizations, mortality, functional capacity, quality of life, and healthcare costs over one, two, and five years.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 40 and older with symptoms of heart failure and at least two risk factors for the condition.
Not a fit: Patients who have previously been diagnosed with heart failure or have undergone renal replacement therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier diagnosis and treatment of heart failure, improving patient outcomes and quality of life.
How similar studies have performed: Other studies have shown promise in home-based screening approaches for heart failure, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Age ≥40 years, and at least one of the following symptoms of HF, and at least two risk factors for HF: Symptoms * Dyspnoea on exertion * Dyspnoea at rest * Orthopnoea * Paroxysmal nocturnal dyspnoea * Reduced exercise tolerance, increased time to recover after exercise * Fatigue, tiredness * Ankle swelling Risk factors * Diabetes (type 1 or type 2) * Coronary artery disease (myocardial infarction or coronary artery bypass grafting or percutaneous coronary intervention) * Persistent or permanent atrial fibrillation (not paroxysmal atrial fibrillation) * Previous ischemic or embolic stroke * Peripheral arterial disease (previous surgical or percutaneous revascularisation) * Chronic kidney disease * Regular loop diuretic use (any dose at any dosing interval) for \>30 days * COPD (diagnosis by respiratory physician, radiological emphysema or treatment with advocated COPD therapy) Exclusion Criteria: * Previous diagnosis of HF * Previous renal replacement therapy * Inability to comply with study procedures or provide informed consent
Where this trial is running
Uppsala
- Uppsala Akademiska Hospital — Uppsala, Sweden (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.